STERIS (STE) Stock: Buy, Sell, or Hold?
STE - STERIS plc
$221.48
-3.70 (-1.64%)
▼
5d:
+1.94%
30d:
+6.08%
90d:
+5.15%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When STE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: STE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: STE shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$314.09
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$195.02
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: STE is currently trading at $221.48, which is considered extended relative to its 30-day fair value range of $207.35 to $218.66. The stock's valuation (Forward PE: 20.0) is in line with its historical norms (20.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This pessimistic expectation contrasts with the company's recent 14.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, STE is in a uptrend. The price is approaching resistance at $226.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: STE scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $259.17 (+17.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, STE is in a uptrend. The price is approaching resistance at $226.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: STE scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $259.17 (+17.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$207.35 -
$218.66
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.2%
Protect Your Profits
Holding STE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (18/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($259.17)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$207.35 -
$218.66
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$207.96
Resistance Level
$226.72
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.99
Wall Street Target
$259.17
(+17.0%)
Revenue Growth (YoY)
7.3%
Earnings Growth (YoY)
14.0%
Profit Margin
13.3%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
20.0 vs 20.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$218.16
(-2%)
2-Year Target
$214.89
(-3%)
3-Year Target
$211.66
(-4%)
3-Yr Target (if PE normalizes)
(PE: 20→21)
$221.28
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.0, Growth: 8.6%)
$283.80
(+28%)
Base:
(SPY PE: 19.9, Growth: 8.6%)
$281.94
(+27%)
Bear:
(PE: 16.9, Growth: 8.6%)
$239.65
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 27.53 | Current EPS (TTM): $8.18
Bull Case
$335.48
(+52%)
Analyst growth 35.4%, PE expands to 30.3
Base Case
$304.98
(+38%)
Market implied 35.4%, PE stable at 27.5
Bear Case
$153.12
(-31%)
Severe decline -20.0%, PE contracts to 23.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.0 to 20.9
Stabilization Target:
$231.55
(+4.5%)
PE Expansion Potential:
+4.5%
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is STE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 50 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 59 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 53 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
CATX
Perspective Therapeutics… |
STRONG BUY
14 analysts |
$12 | 60 HOLD |
Advanced STE Option Strategies
Professional options setups generated by AI based on today's STE price and gamma walls.
